Research
Hormonal
Adaptive thermogenesis is primarily driven by the energy deficit itself rather than the resulting loss of body mass, as evidenced by the early onset of reduced REE before significant body composition changes occur.
Your body starts saving energy almost immediately when you cut calories, even before you lose much weight. This suggests the act of eating less triggers the metabolic slowdown, not just the fact that you are lighter.
GoodQualifiesHIGH confidence
this adaptive thermogenesis seems to be mainly attributable to the energy restriction, since it appeared early in the weight-loss programme, before any major changes in body weight or composition were observed.
Why this rating
Strong observational data within the RCT showing early REE drops despite unchanged FFM.
Source
Evidence for the existence of adaptive thermogenesis during weight loss
Éric Doucet et al. · British Journal Of Nutrition · 2001
DOI 10.1079/bjn2001348
rct · n=35Cited 157×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Prolonged energy restriction induces adaptive thermogenesis, causing resting energy expenditure (REE) to fall significantly more than predicted by changes in body composition alone, thereby creating an energetic efficiency that hinders weight loss.Good
- Women may experience a complete resolution of adaptive thermogenesis once weight stability is achieved, whereas men may retain a lower-than-predicted REE even after weight stabilization.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →